Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,522,000 | 7,511,000 | 6,951,000 | 6,532,000 | 7,616,000 |
| Marketable Securities | 417,000 | 222,000 | 331,000 | 312,000 | 351,000 |
| Receivables | 7,929,000 | 8,138,000 | 7,972,000 | 7,327,000 | 6,925,000 |
| Inventories | 6,488,000 | 6,708,000 | 6,954,000 | 6,639,000 | 6,194,000 |
| TOTAL | $25,996,000 | $24,839,000 | $24,468,000 | $23,153,000 | $23,656,000 |
| Non-Current Assets | |||||
| PPE Net | 11,816,000 | 11,504,000 | 11,395,000 | 10,932,000 | 10,658,000 |
| Investments And Advances | 918,000 | 951,000 | 958,000 | 907,000 | 886,000 |
| Intangibles | 29,561,000 | 29,569,000 | 29,872,000 | 29,620,000 | 29,755,000 |
| Other Non-Current Assets | 18,422,000 | 17,318,000 | 17,306,000 | 16,836,000 | 16,459,000 |
| TOTAL | $60,717,000 | $59,342,000 | $59,531,000 | $58,295,000 | $57,758,000 |
| Total Assets | $86,713,000 | $84,181,000 | $83,999,000 | $81,448,000 | $81,414,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 3,033,000 | 1,345,000 | 507,000 | 506,000 | 1,500,000 |
| Accounts payable and accrued liabilities | 4,240,000 | 4,123,000 | 4,306,000 | 4,214,000 | 4,195,000 |
| Accrued Expenses | 1,745,000 | 1,735,000 | 1,550,000 | 1,167,000 | 1,701,000 |
| TOTAL | $16,496,000 | $14,582,000 | $13,439,000 | $13,004,000 | $14,157,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 9,896,000 | 11,596,000 | 12,930,000 | 12,736,000 | 12,625,000 |
| Other Non-Current Liabilities | 7,550,000 | 6,739,000 | 6,801,000 | 6,644,000 | 6,731,000 |
| TOTAL | $17,446,000 | $18,335,000 | $19,731,000 | $19,380,000 | $19,356,000 |
| Total Liabilities | $33,942,000 | $32,917,000 | $33,170,000 | $32,384,000 | $33,513,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,737,683 | 1,738,872 | 1,740,459 | 1,739,836 | 1,734,323 |
| Common Shares | 25,527,000 | 25,412,000 | 25,284,000 | 25,125,000 | 25,153,000 |
| Retained earnings | 49,781,000 | 49,103,000 | 48,467,000 | 47,715,000 | 47,261,000 |
| Other shareholders' equity | -5,360,000 | -6,374,000 | -6,312,000 | -7,164,000 | -7,669,000 |
| TOTAL | $52,771,000 | $51,264,000 | $50,829,000 | $49,064,000 | $47,901,000 |
| Total Liabilities And Equity | $86,713,000 | $84,181,000 | $83,999,000 | $81,448,000 | $81,414,000 |